

# **Resveratrol analogue 4,4'-dihydroxy-*trans*-stilbene potently inhibits cancer invasion and metastasis**

**Monica Savio<sup>+1\*</sup>, Daniela Ferraro<sup>+1</sup>, Cristina Maccario<sup>1</sup>, Rita Vaccarone<sup>3</sup>, Lasse D. Jensen<sup>2,4</sup>, Federica Corana<sup>5</sup>, Barbara Mannucci<sup>5</sup>, Livia Bianchi<sup>1</sup>, Yihai Cao<sup>2</sup> and Lucia Anna Stivala<sup>1\*</sup>**

<sup>1</sup>Department of Molecular Medicine, Immunology and General Pathology Unit, University of Pavia, Pavia, Italy;

<sup>2</sup>Department of Microbiology, Tumour and Cell Biology, Karolinska Institute, Stockholm, Sweden;

<sup>3</sup>Department of Biology and Biotechnology, Comparative Anatomy and Cytology Laboratory, University of Pavia, Pavia, Italy;


<sup>4</sup>Department of Medical and Health Sciences, Linköping University, Linköping, Sweden

<sup>5</sup>Centro Grandi Strumenti, University of Pavia, Pavia, Italy.

<sup>+</sup>These authors contribute equally to this work

\*Corresponding authors: [monica.savio@unipv.it](mailto:monica.savio@unipv.it), [luciaanna.stivala@unipv.it](mailto:luciaanna.stivala@unipv.it)


## EMT transition



Epithelial-mesenchymal transition, evaluated by using E-cadherin and Vimentin antibodies, was not detected both in control and DHS-treated liver metastases (arrows, X100 magnification objective).

Supplemental Figure S1

## HUVEC BrdU incorporation



DHS significantly inhibited BrdU incorporation starting from 5 µM with a reduction of 35% with respect to HUVEC control cells ( $p < 0.05$ ). In the range 30-60-90 µM DHS inhibited completely (100%) the DNA synthesis (data not shown).

### Supplemental Figure S2